The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Predictors of HIV Drug‐Resistance Mutations in a Large Antiretroviral‐Naive Cohort Initiating Triple Antiretroviral Therapy
Open accessAbstract
OBJECTIVE: The objective of this study was to systematically characterize the incidence and determinants of antiretroviral resistance in the HOMER (Highly Active Antiretroviral Therapy [HAART] Observational Medical Evaluation and Research) cohort of 1191 human immunodeficiency virus-infected, antiretroviral-naive adults initiating HAART in British Columbia, Canada. METHODS: All plasma samples with plasma virus loads (pVLs) >1000 copies/mL collected during the first 30 months of follow-up were genotyped for drug resistance. The primary outcome measure was time to the first detection of major drug-resistance mutation(s). Cox proportional hazard regression was used to identify factors significantly associated with the detection of drug-resistance mutations. RESULTS: Drug-resistance mutations were detected in 298 subjects (25%). Factors significantly associated with detection of drug-resistance mutations included high baseline pVL (multivariate hazard ratio [HR], 1.59; P<.001) and adherence (estimated using prescription-refill data and/or untimed plasma drug-concentration measurements). When compared with subjects with low (0%-<20%) prescription-refill percentages, subjects at an elevated risk of harboring drug-resistance mutations were those with relatively high but imperfect prescription-refill percentages (80%-<90%; multivariate HR, 4.15; P<.001) and those with essentially perfect (>/=95%) refill percentages but with 2 plasma drug concentrations below the steady-state trough concentration minus 1 standard deviation (multivariate HR, 4.57; P<.001). Initial use of nonnucleoside reverse-transcriptase inhibitor-based HAART was significantly associated with multiclass drug resistance (multivariate HR, 1.84; P=.001). CONCLUSION: High baseline pVLs and substantial but imperfect levels of adherence were major predictors of antiretroviral resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection
Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., Squier, C., Wagener, M. M., & Singh, N. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-1-200007040-00004 · Cited by 3,289
Egger, M., May, M., Chêne, G., Phillips, A. N., Ledergerber, B., Dabis, F., Costagliola, D., Monforte, A. D., de Wolf, F., Reiss, P., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09411-4 · Cited by 1,525
Self-citationNon-adherence to highly active antiretroviral therapy predicts progression to AIDS
Bangsberg, D. R., Perry, S., Charlebois, E. D., Clark, R. A., Roberston, M., Zolopa, A. R., & Moss, A. (2001) · AIDS · doi:10.1097/00002030-200106150-00015 · Cited by 960
Ledergerber, B., Egger, M., Opravil, M., Telenti, A., Hirschel, B., Battegay, M., Vernazza, P., Sudre, P., Flepp, M., Furrer, H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01122-8 · Cited by 906
Hirsch, M. S., Brun-Vézinet, F., D'Aquila, R. T., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Loveday, C., Mellors, J. W., Clotet, B., Conway, B., et al. (2000) · JAMA · doi:10.1001/jama.283.18.2417 · Cited by 766
Hogg, R. S. (2001) · JAMA · doi:10.1001/jama.286.20.2568 · Cited by 728
Self-citationHirsch, M. S., Günthard, H. F., Schapiro, J. M., Brun‐Vézinet, F., Clotet, B., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Mellors, J. W., Pillay, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/589297 · Cited by 573
Schuurman, R., Nijhuis, M., van Leeuwen, R., Schipper, P., de Jong, D., Collis, P., Danner, S. A., Mulder, J., Loveday, C., Christopherson, C., et al. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1411 · Cited by 503
Correction: Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection
(2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-3-200202050-00020 · Cited by 502
Sethi, A. K., Celentano, D. D., Gange, S. J., Moore, R. D., & Gallant, J. E. (2003) · Clinical Infectious Diseases · doi:10.1086/378301 · Cited by 475
Hogg, R. S., Heath, K., Bangsberg, D., Yip, B., Press, N., O'Shaughnessy, M. V., & Montaner, J. S. G. (2002) · AIDS · doi:10.1097/00002030-200205030-00012 · Cited by 425
Self-citationDeeks, S. G., Hecht, F. M., Swanson, M., Elbeik, T., Loftus, R., Cohen, P. T., & Grant, R. M. (1999) · AIDS · doi:10.1097/00002030-199904160-00001 · Cited by 417
The prevalence of antiretroviral drug resistance in the United States
Richman, D. D., Morton, S. C., Wrin, T., Hellmann, N., Berry, S., Shapiro, M. F., & Bozzette, S. A. (2004) · AIDS · doi:10.1097/01.aids.0000131310.52526.c7 · Cited by 408
Hogg, R. S., Yip, B., Kully, C., Craib, K. J. P., O’Shaughnessy, M. V., Schechter, M. T., & Montaner, J. S. G. (1999) · Europe PMC (PubMed Central) · Cited by 316
Self-citationHavlir, D. V. (2000) · JAMA · doi:10.1001/jama.283.2.229 · Cited by 297
Adherence to Triple Therapy and Viral Load Response
Low-Beer, S., Yip, B., O'Shaughnessy, M. V., Hogg, R. S., & Montaner, J. S. G. (2000) · Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200004010-00016 · Cited by 285
Self-citationDrug Resistance Mutations in HIV-1.
D’Aquila, R. T., Schapiro, J., Brun‐Vézinet, F., Clotet, B., Conway, B., Demeter, L. M., Grant, R. M., Johnson, V. A., Kuritzkes, D. R., Loveday, C., et al. (2002) · PubMed · Cited by 276
High levels of adherence do not prevent accumulation of HIV drug resistance mutations
Bangsberg, D. R., Charlebois, E. D., Grant, R. M., Holodniy, M., Deeks, S. G., Perry, S., Conroy, K. N., Clark, R., Guzman, D., Zolopa, A., et al. (2003) · AIDS · doi:10.1097/00002030-200309050-00011 · Cited by 256
Impact of drug resistance mutations on virologic response to salvage therapy
Lorenzi, P., Opravil, M., Hirschel, B., Chave, J.-P., Furrer, H.-J., Sax, H., Vaclav Perneger, T., Perrin, L., Kaiser, L., & Yerly, S. (1999) · AIDS · doi:10.1097/00002030-199902040-00001 · Cited by 205
Attaining higher goals in HIV treatment: the central importance of adherence.
Friedland, G. H., & Williams, A. (1999) · PubMed · Cited by 204
Brumme, Z. L., Dong, W. W. Y., Yip, B., Wynhoven, B., Hoffman, N. G., Swanstrom, R. I., Jensen, M. A., Mullins, J. I., Hogg, R. S., Montaner, J. S. G., et al. (2004) · AIDS · doi:10.1097/00002030-200403050-00001 · Cited by 94
Self-citationWalsh, J. C., Pozniak, A., Nelson, M. R., Mandalia, S., & Gazzard, B. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200207010-00003 · Cited by 89
Maguire, M. F., Gartland, M., Moore, S., Hill, A. M., Tisdale, M., Harrigan, R., & Kleim, J. (2000) · AIDS · doi:10.1097/00002030-200006160-00017 · Cited by 69
Palepu, A., Yip, B., Miller, C. L., Strathdee, S. A., O’Shaughnessy, M. V., Montaner, J. S. G., & Hogg, R. S. (2001) · AIDS · doi:10.1097/00002030-200102160-00021 · Cited by 55
Self-citationAlexander, C. S., Asselin, J. J., Ting, L. S. L., Montaner, J. S. G., Hogg, R. S., Yip, B., O’Shaughnessy, M. V., & Harrigan, P. R. (2003) · The Journal of Infectious Diseases · doi:10.1086/376835 · Cited by 55
Self-citationRomanó, L., Venturi, G., Giomi, S., Pippi, L., Valensin, P. E., & Zazzi, M. (2001) · Journal of Medical Virology · doi:10.1002/jmv.2123 · Cited by 33
Vidal, C., Arnedo, M., García, F., Mestre, G., Plana, M., Cruceta, A., Capón, A., Gallart, T., Miró, J. M., Pumarola, T., et al. (2002) · Antiviral Therapy · doi:10.1177/135965350200700408 · Cited by 16
Cited by
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Thompson, M. A., Mugavero, M. J., Amico, K. R., Cargill, V. A., Chang, L. W., Gross, R., Orrell, C., Altice, F. L., Bangsberg, D. R., Bartlett, J. G., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-11-201206050-00419 · Cited by 582
Bangsberg, D. R. (2006) · Clinical Infectious Diseases · doi:10.1086/507526 · Cited by 534
Shubber, Z., Mills, E. J., Nachega, J. B., Vreeman, R., Freitas, M., Bock, P., Nsanzimana, S., Penazzato, M., Appolo, T., Doherty, M., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002183 · Cited by 526
Nachega, J. B., Hislop, M., Nguyen, H., Dowdy, D. W., Chaisson, R. E., Regensberg, L., Cotton, M., & Maartens, G. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318199072e · Cited by 449
Metadata
- Authors
- Harrigan, P. R., Hogg, R. S., Dong, W. W. Y., Yip, B., Wynhoven, B., Woodward, J., Brumme, C. J., Brumme, Z. L., Mo, T., Alexander, C. S., & Montaner, J. S. G.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-02
- Volume
- 191
- Issue
- 3
- Pages
- 339-347
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2047734031
- Cited by
- 424
- References
- 28
- FWCI
- 18.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.